Promotional material

Vaccine update: issue 361, July 2025

Published 1 August 2025

Applies to England

Think measles!

More than 1 in 10 eligible children under the age of 5 in England haven’t had the measles mumps and rubella (MMR) vaccine or are only partially vaccinated.

This leaves these children unprotected and increases the risk of measles outbreaks occurring in nurseries and schools. We are reminding parents and guardians to ensure their children are protected by taking up 2 doses of the MMR vaccine at the right time.

Over the past decade, there has been a slow decline in the number of parents and carers getting their children vaccinated with the MMR and other childhood vaccines. Measles is highly contagious, so even a small decline in MMR uptake can lead to a rise in cases. In 2024 there were 2,911 laboratory confirmed measles cases in England, the highest number of cases recorded annually since 2012. Outbreaks have continued this year and more recently measles activity has increased in London and the North West Regions. Most of the cases have been in unvaccinated children under the age of 10.

We have also seen a resurgence of measles in Europe after the COVID-19 pandemic. As families prepare for travel over the summer break, there is more chance for measles to be brought in from countries where there are outbreaks. Catching up children who missed out on their MMR vaccines is a priority, in order to help prevent another rise in measles cases.

Change to the MMR schedule

From 1 January 2026, children born on or after 1 July 2024 will be offered the second dose of MMR vaccine at a new 18-month vaccination appointment. Children born before 1 July 2024 who are still due their second MMR dose will continue to have it at their pre-school appointment at 3 years and 4 months. The second dose of the MMR vaccine is being brought forward for children born after 1 July 2024 in an attempt to improve uptake of the MMR vaccine and should help us achieve the World Health Organization 95% uptake target needed to prevent outbreaks in the community.

You can read more about the childhood changes in Vaccine update issue 359.

Two doses of MMR for full protection

The MMR vaccine is the safest and most effective way to protect yourself against measles, mumps and rubella. Over 99% of those who have 2 doses of the MMR vaccine will be protected against measles and rubella. Although mumps protection is slightly lower, cases in vaccinated people are much less severe.

Since the MMR vaccine was introduced in 1988, these conditions have become rare in the UK. However, outbreaks of disease, especially measles, have occurred when the number of people having the vaccine has dropped. The fall in MMR uptake over the past decade explains the rise in measles cases we have subsequently seen in the UK since 2023.

Measles rates internationally

Since the introduction of the measles vaccine in 1968, 20 million measles cases and 4,500 deaths have been prevented in the UK. However, countries around the world with low MMR vaccine uptake continue to experience large measles outbreaks and epidemics. It is especially important to check you are up to date with your 2 doses of MMR before you travel. Not only would it be unpleasant to become ill while abroad, you may risk bringing the infection back with you and exposing your family and friends.

Vaccination for older children and adults

Anyone who has not had 2 doses of the MMR vaccine can contact their GP surgery to book an appointment. It is never too late to catch-up. It’s important to check you’ve had both doses if you are:

• about to start college or university
• going to travel abroad
• planning a pregnancy
• a frontline health or social care worker

More information on catching up with MMR doses can be read in the UKHSA blog on this topic.

Have you read about Saijal Ladd, Prescribing Advisor – Medicines Planning and Operations, NHS North Central London Integrated Care Board (ICB), who has written about her experience of contracting measles at 42, and the serious impact this had on her health? Read her UKHSA blog.

Advice for travellers

When setting off to travel abroad, it is important to check a few things off your list of preparations:

• consider having a vaccination against hepatitis A for you and your family
• make sure you are you tick and mosquito aware
• find out if there is a risk of rabies in the country you are visiting

Mosquito health advice for travellers

There is health advice for travellers to reduce the risk of acquiring mosquito-borne infections such as chikungunya, dengue, Japanese encephalitis, malaria, West Nile virus, yellow fever and Zika. It was developed by the UK Health Security Agency (UKHSA) and the National Travel Health Network and Centre (NaTHNaC).

Copies of our leaflet on mosquito health advice for travel are available to view online or order now from Health Publications, product code: MOSTRA1EN.

This guidance is also available in the following formats:

• Mosquito bite avoidance: advice for travellers – YouTube video
• Mosquito bite avoidance: advice for travellers – video download
• Mosquito health advice for travellers – large print version (to download)
•  How to stop bugs biting you abroad – easy-read version (to download)
• Mosquito bite avoidance: advice for travellers – British Sign Language (BSL) video version (to download)
• Mosquito bite avoidance: advice for travellers – audio version (to download)
• Mosquito bite avoidance: advice for travellers – Braille version (to order)

This leaflet has been translated into these languages and are available to download: Arabic, Bengali, French, Gujarati, Hausa, Igbo, Punjabi, Spanish, Swahili, Yoruba, Urdu, Xhosa.

Rabies

Rabies is a rare but deadly viral infection that affects the brain and nervous system. Human cases of rabies are extremely rare in the UK, but the infection poses a risk to travellers visiting countries where the disease remains prevalent.

It is typically transmitted to people through contact with saliva via the bite or scratch of an infected animal. Dogs are the most common source of infections in people, but other animals can also pass on rabies, including cats, bats and monkeys. Rabies is almost always fatal once symptoms appear, but it can be prevented by a course of vaccines given promptly after an exposure (post-exposure treatment).

Preparing for travel abroad

If you are travelling to a country where rabies is present in animals, it’s important to know how to prevent the infection and what actions to take following potential exposure.

There is information on the Travel Health Pro website about which countries are affected by rabies and when you should consider a course of rabies vaccines before travel.

Preventing rabies while travelling

Prevention is crucial when visiting countries where rabies is present in animals, particularly in parts of Asia, Africa, and Central and South America. Travellers should consider these preventive measures:

• consulting a travel health professional before taking a trip to determine if pre-exposure vaccination is recommended based on their destination and planned activities
• vaccination is particularly important if they will be staying for over a month, engaging in outdoor activities or travelling to areas with limited access to medical care
• the rabies vaccine is given as an injection – travellers usually have 3 doses given over 28 days, so it’s important to plan ahead to allow them to receive all 3 doses before they travel
• while abroad, avoiding contact with animals as much as possible, including dogs, cats, monkeys and other wildlife, to reduce their risk of exposure
• infected animals may not always display obvious symptoms of disease – it’s important to tell children to avoid touching animals and, if they do, to let you know about any bites or scratches straight away

Responding to potential exposure

If someone is bitten, scratched or licked on broken skin by an animal in a country where rabies is present in animals, they should take these immediate steps:

1. Thoroughly wash the wound with plenty of soap and lots of water for several minutes. This simple measure can significantly reduce the risk of infection.
2. Seek local medical attention without delay – even if they have been vaccinated before travelling. Don’t wait until return to the UK. Post-exposure treatment is highly effective when administered promptly, before symptoms develop.
3. Contact their GP on return to the UK, even if they received post-exposure treatment abroad or the exposure happened several weeks ago. They may need to continue a course of rabies vaccines. If they have a record of any treatment given, this should be bought with them. Their GP will also be able to arrange for post-exposure treatment if this hasn’t been started while they were abroad but is considered necessary by UKHSA.

The UK is free from rabies in terrestrial animal populations, but rabies-like viruses have been found in some bats in the UK. If you’re bitten by a bat in the UK, contact your doctor promptly for assessment and possible vaccination.

Vaccine effectiveness

A full course of pre-exposure rabies vaccines will provide good protection from rabies for most people. People who completed their full course of rabies pre-exposure vaccine over a year ago and are travelling again to a high-risk area for rabies can have a single booster dose.

However, it is still important to seek medical advice if you are bitten, scratched or licked on broken skin by an animal overseas. If you had a full course of pre-exposure vaccines before travel, even years beforehand, you will only need 2 additional rabies vaccine doses after an exposure and will not need immunoglobulin. For individuals with severe immunosuppression, the post-exposure treatment course may be slightly different. Seven human rabies cases have been reported in the UK between 2000 and 2025 in individuals who acquired the infection overseas.

Rabies in the UK

The UK has been free from rabies in animals other than bats since 1902, making domestic infection extremely rare.

Information leaflets on rabies

Rabies: information for travellers is available to download or order from Health Publications, product code: 4000322RT. This document contains information on:

• rabies risks from animals overseas
• considerations before travelling
• minimising contact with animals while abroad
• how to treat an animal bite, scratch or lick
• specialist advice for health professionals

For more information, visit NaTHNAC TravelHealthPro.

Health professionals can contact the UKHSA Rabies and Immunoglobulin Service (RIGS) on 0330 128 1020 between 9am and 5pm, 7 days a week.

Bat contact and rabies risks is available to download and order from Health Publications, product code: 400321BT.

This document contains information on:

• bat rabies
• the risk of catching rabies after being bitten by a bat
• how to treat a bat bite after exposure
• specialist advice for health professionals

RSV updates

Nirsevimab selective RSV immunisation programmes

This winter a new NHS nirsevimab selective immunisation programme will be protecting very and extremely premature infants against respiratory syncytial virus (RSV). These are babies born before they can be protected by mum’s antenatal RSV vaccination. The current programme of palivizumab injections for high-risk children will also be replaced with one injection of nirsevimab.

UKHSA has been working closely with the Joint Committee on Vaccination and Immunisation (JCVI) and the NHS to provide evidence in support of this programme, and we are delighted to see this launch ahead of winter 2025. Very premature babies are 3 times more likely to need to be admitted to hospital for RSV than full-term babies. High-risk babies will get higher protection and not need monthly injections.

Nirsevimab is a one-off injection given in children’s hospitals and clinical teams will advise parents if their infant needs it based on recently updated Green book criteria. It is ordered by hospital pharmacies through Phoenix Healthcare Distribution Ltd.

A new nirsevimab leaflet is in preparation and will be available soon alongside the pre-existing RSV patient information materials.

The RSV maternal vaccination programme Information for healthcare practitioners and training slide set have been updated.

RSV immunisation – rare risk of Guillain-Barré in older adults and advice to seek medical care

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug safety update to health professionals advising that there is a rare risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer RSV vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital. Early treatment can help avoid the most serious complications and aid recovery.

Information given to older adults receiving vaccination has advised of a rare risk since the introduction of the programme in September 2024. The UKHSA older adult leaflet has been updated with the latest incidence estimates and the latest MHRA advice. The RSV older adult vaccination programme Information for healthcare practitioners and training slide set have been updated.

There is no evidence to date of any increased risk in pregnant women. Guillain-Barré syndrome of any cause is very rare in pregnancy.

Co-administration of RSV vaccines with COVID-19 vaccines

JCVI has assessed new data on co-administration and advised that older adults’ RSV vaccines can be routinely scheduled alongside COVID-19 vaccines. This has been updated in the Green book. There is no change to advice that RSV and influenza vaccines should not ordinarily be scheduled on the same day, due to possible impact on immune response to both, though this can be done if it is thought that the individual is unlikely to return for a second appointment or immediate protection is necessary.

Mpox and meningococcal B vaccine for GBMSM in specialist sexual health services

New routine mpox and 4CMenB for gonorrhoea vaccination programmes, primarily for gay, bisexual and other men who have sex with men (GBMSM) at higher risk of acquiring these infections, delivered by local authority commissioned sexual health services from 1 August 2025. We featured the programme in Vaccine update issue 360 – refer to this edition for further details.

UKHSA is measuring the uptake, impact and effectiveness of 4CMenB and mpox vaccination for gonorrhoea using GUMCAD data

GUMCAD is the national sexually transmitted infections (STI) surveillance system for England.

See the tables below for the Sexual Health and HIV Activity Property Types (SHHAPT) codes co-developed with healthcare practitioners (HCPs) and the British Association for Sexual Health and HIV (BASHH)/Faculty of Sexual and Reproductive Health (FSRH) information group.

4CMenB SHHAPT codes

SHHAPT Code	Definition
MBVD1	1st dose 4CMenB
MBVD2	2nd dose 4CMenB
MBVDX	Course of 4CMenB completed at another SHS
MBVD0	Declined 4CMenB vaccination

Mpox SHHAPT codes

SHHAPT Code	Definition
MPVD1	1st dose mpox
MPVD2	2nd dose mpox
MPVD4	Course of mpox vaccination completed previously or at another SHS
MPVDX	Declined mpox vaccination
MPVD5	Contraindicated for mpox vaccination

Updated publications

National childhood immunisation campaign postcard

This postcard is available to download now featuring the updated schedule for children born on or after 1 July 2024.

Download from Health Publications, product code: CHIMMS25PCEN

Vaccines and porcine gelatine leaflet

This leaflet has been updated to align it with the childhood vaccination schedule from 1 July 2025.

The issue of some vaccines that contain ingredients derived from pigs (in this case gelatine – known as ‘porcine’ gelatine) has concerned some faith groups. This leaflet provides information about vaccines that contain porcine gelatine and any alternatives that are available.

This leaflet is available for download from Health Publications only, using the product code 2025PGVEN.

Translations of this leaflets are available to download in: Arabic, Bengali, Gujarati, Panjabi and Urdu.

Vaccine supply: routine vaccination programme

Attention all ImmForm customers: August Bank Holiday deliveries

Due to the August Bank Holiday, there will be no deliveries or order processing by Movianto UK on Monday 25 August 2025. See the table below for your revised order and delivery days and the additional information for offshore and COVID-19 vaccine customers.

All customers should prepare for the break in deliveries and order accordingly.

Ensure you have enough room in your fridge for any additional vaccine that you order in advance of this holiday period, bearing in mind the recommendation that only 2 to 4 weeks of vaccine stock should be held locally.

No emergency or out-of-schedule deliveries can be arranged for ImmForm customers who fail to place their orders in good time.

Delivery date	Order cut-off date	Order cut-off time
Monday 18 August 2025	Thursday 14 August 2025	11.55am
Tuesday 19 August 2025	Friday 15 August 2025	11.55am
Wednesday 20 August 2025	Monday 18 August 2025	11.55am
Thursday 21 August 2025	Tuesday 19 August 2025	11.55am
Friday 22 August 2025	Wednesday 20 August 2025	11.55am
Monday 25 August 2025	Closed – No deliveries or order processing	-
Tuesday 26 August 2025	Thursday 21 August 2025	11.55am
Wednesday 27 August 2025	Friday 22 August 2025	11.55am
Thursday 28 August 2025	Tuesday 26 August 2025	11.55am
Friday 29 August 2025	Wednesday 27 August 2025	11.55am
Monday 1 September 2025	Thursday 28 August 2025	11.55am

Offshore customers

Isle of Wight and Isle of Man: see the table above for your revised order and delivery days.

Jersey, Guernsey, Shetland, Stornoway and Orkney: the first ‘hand to the courier’ day after the August Bank Holiday is Tuesday 26 August 2025, with the first ‘final mile’ delivery day being Wednesday 27 August 2025. The order cut-off for this is Thursday 21 August 2025.

COVID-19 vaccine offshore customers

For Guernsey and Scottish islands with a final mile delivery day of Tuesday: there will be no deliveries of COVID-19 vaccine on Tuesday 26 August to Guernsey, Shetland, Orkneyor Western Isles. The next available delivery day will be Tuesday 2 September 2025.

For Jersey, Isle of Man and Scottish islands with a final mile delivery day of Wednesday: there will be no deliveries of COVID-19 vaccine on Wednesday 27 August 2025 to Jersey, Isle of Man, Shetland, Orkney or Western Isles. The next available delivery day will be Wednesday 3 September 2025.

Changes to the routine childhood vaccination schedule since 1 July 2025

The routine childhood vaccination schedule changed on 1 July 2025. All vaccines required to support the routine childhood vaccination schedule remain available to order via ImmForm.

Providers should note that Menitorix® is no longer offered to children turning one year old from 1 July 2025 onwards. Menitorix® will remain available to order via ImmForm only for those children previously eligible for it. Once central supplies of Menitorix® deplete, those previously eligible children should be offered a dose of DTaP/Hib/IPV/HepB vaccine, also available via ImmForm.

Details of the changes to the routine immunisation schedule are available at The complete routine immunisation schedule.

Meningococcal B (Men B) vaccination for protection against gonorrhoea

From summer 2025, meningococcal B (MenB) vaccination for protection against gonorrhoea will be offered by specialist sexual health services to GBMSM.

Bexsero® (Men B) vaccine is now available via ImmForm for sexual health services. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland should refer to their local ordering restrictions.

For customers that also access Bexsero® for the infant immunisation programme, when ordering Bexsero® orders should be placed for the ImmForm product that is specific to the programme for which the stock is intended. Bexsero® ordered for the infant immunisation protection programme should not be used for the GBMSM gonorrhoea protection programme and vice versa.

Bexsero® vaccine ordered via ImmForm is supplied as a 10-dose pack, containing 10 pre-filled syringes of vaccine and one patient information leaflet (PIL). Each 10-dose pack of Bexsero® vaccine ordered via ImmForm is supplied with a pad of 10 additional PILs.

The 10-dose pack of Bexsero® vaccine supplied via ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book chapter 4. Needles should be obtained locally.

Please add Bexsero® vaccine to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, order no more than 2 weeks’ worth of stock.

Details about meningococcal B (Men B) vaccination for use against gonorrhoea can be found in the on the guidance leaflet.

Further details about Bexsero® vaccine can be found in the patient information leaflet (PIL).

Contact the helpdesk@immform.org.uk for ordering queries.

Introduction of routine mpox vaccination programme

From summer 2025, a new routine mpox vaccination programme, primarily for GBMSM, will be offered by some sexual health services.

From late July 2025, those sexual health services in England will be able to order Imvanex® (mpox) vaccine via ImmForm. Updated information on ordering dates for England and country-specific ordering dates for other customers will be made available via ImmForm in due course.

High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland and Wales should refer to their local ordering restrictions.

Imvanex® vaccine ordered via ImmForm will be supplied as a 10-dose pack, containing 10 vials (10 x 0.5ml) of vaccine and one PIL. Each 10-dose pack of Imvanex® vaccine ordered via ImmForm will be supplied with a pad of 10 additional PILs and a ‘Dear healthcare professionals’ (DHCP) letter explaining the provision of a non-UK licensed pack.

Imvanex® vaccine ordered via ImmForm will be delivered to customers on their routine weekly delivery day, in an isothermic shipper with an internal temperature of –20°C. The isothermic shipper will be recycled by Movianto who will either retain the shipper at the time of delivery to ImmForm customers or arrange for its collection on a later date. ImmForm customers should therefore not dispose of the isothermic shipper.

Upon receipt of Imvanex® vaccine ordered via ImmForm, customers can continue to store the Imvanex® vaccine at –20°C to retain the –20°C expiry shown on the delivery note and pack. Alternatively, customers can store Imvanex® vaccine at 2 to 8°C with the vaccine then having an expiry date of 8 weeks from the time when the vaccine is removed from its –20°C storage.

The 10-dose pack of Imvanex® vaccine supplied via ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book, chapter 4. Needles should be obtained locally.

To help with planning storage requirements, the dimensions of the 10-dose pack of Imvanex® vaccine are 54 x 38 x 92mm (H x W x D).

To minimise wastage due to fridge failures, order no more than 2 weeks’ worth of stock.

Details about mpox vaccination can be found at Introduction of new routine mpox and 4cmenb for gonorrhoea vaccination programmes letter. Additional programme resources are available at Vaccination against mpox.

Further details about Imvanex® vaccine can be found in the manufacturer’s Summary of product characteristics (SmPC)

Contact the helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2025 to 2026 children’s flu programme supplied by UKHSA

The latest and most accurate information on the availability and allocation of vaccines for the children’s flu programme is available on the ImmForm news page.

All information remains subject to change. If you are a provider of the children’s flu programme, ensure you are checking ImmForm regularly.

All flu vaccines for the 2025 to 2026 children’s flu programme will be available to order by general practice and the school-age immunisation service in England via ImmForm.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Vaccines and availability

The 2 vaccines that will be available, preliminary indicative ordering dates and the groups that these vaccines should be ordered for are set out in the table below.

Vaccine	Manufacturer	Available to order for	Anticipated order opening for all providers
Fluenz® (LAIV)	AstraZeneca	All children from 2 years of age to school year 11 Children in clinical risk groups aged 2 to <18 years [note 1]	Early September
Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc)	Seqirus	Children in clinical risk groups aged 6 months to <2 years  All other eligible [note 2] children aged 2 to <18 years for whom LAIV is unsuitable	Early September

Note 1: Unless LAIV clinically contraindicated or otherwise unsuitable Note 2: Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to less than 18 years

Children’s flu vaccine supply for programme delivery innovation

We are aware of increasing activity across England, in particular by primary care networks (PCNs), to deliver the programme to 2 and 3 year olds via innovative models (such as in a nursery setting). If you are planning any such activity, we advise that you contact childfluvaccine@ukhsa.gov.uk to discuss your plans. This will enable us to support you with any additional supply requirements or any other supply-related advice

LAIV ordering information for general practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls will work by allocating an amount of LAIV based on the umber of registered eligible patients and will be tailored to each practice.

UKHSA expects to be able to accommodate the following, however at this time, this information remains subject to change:

• each GP practice will initially be allocated sufficient LAIV to vaccinate at least 45% of its eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to less than 18 years) when ordering commences
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period – requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off (out-of-schedule deliveries will be by exception only)

This vaccine has a short shelf life. Try to hold no more than 2 weeks’ stock at a time and re-order regularly to reduce local wastage through expiry before use.

Multi-branch practices and LAIV allocations

GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommend that this agreement is in place before ordering opens to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIV ordering information for school-age providers

A default weekly ordering cap of 450 packs (4,500 doses) per week will be in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example, where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk referencing the relevant ImmForm account number or Org code. Requests should be made by Friday 30 August to ensure that accounts are set up correctly before vaccine ordering commences.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk

Inactivated flu vaccine ordering

The Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc) will be available to order, in a single dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to less than 18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

• for GPs, there will be an initial cap of 10 doses/packs per week

• for school-age providers, there will be a cap of 450 doses/packs per week

Influenza vaccines for the 2025 to 2026 season

Information on all influenza vaccines that will be marketed in the UK for the 2025 to 2026 season are available on the flu vaccination page on GOV.UK.

Impact of changes to opening hours on routine vaccine deliveries

Consider temporary changes to opening times when placing ImmForm orders. Orders should only be placed for days when your site is open and capable of receiving them. If you are aware of a scheduled site closure, refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care on MoviantoUK.NHSCC@movianto.com and 01234 587207. This should not be used to report short-term changes due to absence or holidays.

Depletion of Vaxelis® for DTaP/IPV/Hib/HepB vaccination

The UKHSA stockholding of Vaxelis® has depleted. Infanrix hexa is now the only DTaP/IPV/Hib/HepB vaccine available to order via ImmForm. Orders for Infanrix hexa® remain unrestricted.

Providers should not order more than 2 weeks’ worth of stock to minimise wastage due to fridge failures. For assistance, please contact the ImmForm Helpdesk at helpdesk@immform.org.uk

MMR vaccine ordering

M-M-RvaxPro vaccine should be ordered for all MMR vaccinations, unless a patient requires a porcine gelatine-free MMR vaccine. ImmForm customers in England and Wales may order M-M-RvaxPro vaccine without restriction.

In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix vaccines per account per week.

ImmForm customers in Scotland should refer to their local ordering restrictions.

Both MMR vaccines may only be ordered for outbreak purposes when this is part of a national catch-up campaign

Vaccine supply: non-routine vaccine supply

Hepatitis A vaccine

Adult

GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available.

Sanofi Pasteur: Avaxim PFS singles are currently available. Avaxim packs of 10 are currently available.

MSD: VAQTA Adult is available.

Paediatric

GSK: supply of Havrix Paediatric singles and packs of 10 are currently available.

MSD: VAQTA Paediatric is available.

Sanofi Pasteur: Avaxim Junior singles are currently available.

Hepatitis B vaccine

Adult

GSK: Engerix B PFS singles and packs of 10 are currently available.

GSK: supply of Fendrix is currently available.

MSD: HBVAXPRO 10μg is available.

MSD: HBVAXPRO 40μg is available.

Valneva: PreHevbri is no longer marketed in the UK.

Paediatric

GSK: supplies of Engerix B Paediatric singles are currently available.

MSD: HBVAXPRO 5μg is available.

Combined hepatitis A and B vaccine

GSK: Twinrix Adult singles and packs of 10 are available.

GSK: Twinrix Paediatric is currently available.

GSK: Ambirix is available.

Combined hepatitis A and typhoid vaccine

Sanofi: Viatim is now a discontinued product and no longer available for sale.

Typhoid vaccine

Bavarian Nordic: Vivotif is available.

Sanofi: Typhim singles and packs of 10 are available.

Rabies vaccine

Bavarian Nordic: Rabipur is currently available.

Sanofi: Verorab is currently available.

Pneumococcal polysaccharide vaccine (PPV)

MSD: supply of Pneumovax 23 (PPV23) PFS is available.

Pneumococcal polysaccharide conjugate vaccine (PCV)

Pfizer: Prevenar 13 is currently available.

Pfizer: Prevenar 20 is currently available.

MSD: Vaxneuvance is currently available.

Varicella zoster vaccine

GSK: VARILRIX is currently available.

MSD: VARIVAX is available.

MSD: ZOSTAVAX is a discontinued product.

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine

Sanofi: Revaxis is available.

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

GSK: supply of Boostrix-IPV is currently available.

Sanofi: Repevax is currently available.

MMR vaccine

MSD: MMR VaxPro is currently available.

GSK: Priorix is currently available.

Meningitis ACWY vaccine

GSK: Menveo is currently available.

Pfizer: Nimenrix is currently available.

Sanofi: MenQuadfi is available.

Yellow fever vaccine

Sanofi: Stamaril is currently out of stock until early August.

Human papillomavirus vaccine

MSD: GARDASIL has been discontinued.

MSD: Gardasil 9 is currently available.

GSK: Cervarix has been discontinued.

Cholera vaccine

Bavarian Nordic: Vaxchora is available.

Valneva: Dukoral is available.

Japanese encephalytis vaccine

Valneva: Ixiaro is available.

Meningococcal group B vaccine

GSK: Bexsero is currently available.

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available.

Hib + meningococcal group C combined vaccine

GSK: Menitorix is currently available.

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available.

Herpes zoster vaccine

GSK: Shingrix is currently available.

Diphtheria, tetanus and pertussis

Sanofi: Adacel is currently out of stock but will be available to order without restrictions by mid-July.

Dengue tetravalent vaccine

Takeda: Qdenga is currently available.

Respiratory syncytial virus vaccine

Pfizer: Abrysvo is currently available.

GSK: Arevxy is currently available.

Chikungunya vaccine

Valneva: IXCHIQ®▼ is available. Please read important MHRA Drug Safety update on IXCHIQ® powder and solvent for solution for injection Chikungunya vaccine (live).